Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study – Yahoo Finance

Ocugen Inc (NASDAQ: OCGNannounced results from the Phase 2/3 study of its COVID-19 vaccine candidate, COVAXIN.
COVAXIN has been demonstrated in clinical trials to generate a broader immune response against the whole virus covering important antigens such as S-protein, RBD, and N-protein, whereas currently approved vaccines in the U.S. target only S-protein antigens.
In contrast to other inactivated vaccines, trials have demonstrated that TLR7/8 agonist adjuvant in COVAXIN generates a Th1-biased immune response that induces robust long-term memory B- and T-cell responses.
Related: Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine.
Both co-primary immunogenicity endpoints were met well above the non-inferiority limit with robust immune responses.
Covaxin was found to be well-tolerated in vaccine-naïve individuals and individuals previously vaccinated with mRNA vaccines in the U.S., with no vaccine-related serious adverse events, thrombotic events, or cases of myocarditis or pericarditis.
Price Action: OCGN shares are up 20.8% at $1.57 during the premarket session on the last check Monday.
See more from Benzinga
China In Talks To Secure License For Generic Version Of Pfizer’s COVID-19 Oral Drug
Deere Announces Agreement Allowing Farmers’ Independent Repair Shops Repair High-Tech Tractors
Obama Says Republicans Are ‘Obsessed’ With 2 Things — One Of Them Is Trump
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Quotes
Yahoo Finance's Anjalee Khemlani joins the Live show to discuss John Jacobs replacing Stanley Erck as Novavax CEO. 
MARKET PULSE Shares of Novavax Inc. (NVAX) were up about 9% in trading on Monday after the company said John Jacobs will take over as president and CEO on Jan. 23. Jacobs, the former president and CEO of Harmony Biosciences Holdings Inc.
Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.2 billion.
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
The commercial price for the shot is similar to Pfizer’s plans for after government contracting ends.
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
The idea of a big pharmaceutical company set to offer amazing growth might seem unlikely. Pfizer has been around for more than 170 years. Pfizer said in November that in the full year 2022, it expected to generate more than $55 billion in revenue from the two products combined.
Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
Krystal's candidate to treat dystrophic epidermolysis bullosa candidate, which is sometimes referred to as "butterfly child" due to the fragile-like conditions that become of the skin as a result of the disease, has seen a delay.
China is reportedly in talks with Pfizer Inc (NYSE: PFE) to secure a license allowing domestic drugmakers to manufacture and distribute a generic version of its COVID-19 antiviral Paxlovid. Beijing is keen to finalize licensing deal terms before the Lunar New Year, which begins on January 22. Chinese hospitals are overwhelmed after the government removed its "zero-COVID" policy last month, sending infections soaring. Related: New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid Wit
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals that compensate them for the uncertainty involved. These firms are seeking to capitalize on the growing gap between the supply of capital for clinical research and the number of drugs competing for it, eight buyout executives and investors interviewed by Reuters said. Annual spending on pharmaceutical research and development globally is projected to rise to $254 billion by 2026 from around $200 billion in 2020, according to Evaluate Pharma, a research firm focused on healthcare.
Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.
The CEO of the Mass. chapter of the Alzheimer's Association calls the FDA's approval of Leqembi last week "a disease paradigm change."
MARKET PULSE Shares of Day One Pharmaceuticals Inc. (DAWN) jumped 21% in premarket trading on Monday after the company shared positive data from an ongoing Phase 2 clinical trial for its glioma treatment.
A federal appeals court on Monday declined to revive hundreds of lawsuits by women who claim that GlaxoSmithKline Plc failed to warn them that taking the anti-nausea drug Zofran during pregnancy could cause birth defects. The Boston-based 1st U.S. Circuit Court of Appeals ruled that federal law preempts the plaintiffs' state-law claims that GSK failed to warn doctors and pregnant women that animal studies found a link between birth defects and taking Zofran. The ruling upheld a 2021 ruling by U.S. District Judge F. Dennis Saylor that marked the end of 425 lawsuits consolidated before him in long-running multidistrict litigation.
Cingulate's technology will let patients receive ADHD treatment without second doses or boosters to get through the day.
This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.
Chinese health care authorities declined to include Pfizer's COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive. Paxlovid, an oral medicine developed by New York-based drugmaker Pfizer, has been widely sought after in China since the country began phasing out its “zero-COVID” restrictions and a surge of infections started sweeping through the country. A drug must be included on the reimbursement list to be covered by the national insurance scheme.
For the first time, retail pharmacies can dispense abortion medication pills directly to consumers in states where the procedure is legal, after the Food and Drug Administration made a long-sought rule change in early January. The subsequent decisions by CVS and Walgreens, the two largest drugstore chains in the United States, to seek certification to offer the pills, as required under the rule change, are expected to expand access to the procedure.Subscribe to The Post Most newsletter for the m